Qube Research & Technologies (QRT)
ACAD icon

Qube Research & Technologies (QRT)’s Acadia Pharmaceuticals ACAD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.2M Sell
950,299
-252,302
-21% -$6.03M 0.02% 855
2025
Q4 		$32.1M Buy
1,202,601
+606,159
+102% +$14.5M 0.03% 685
2025
Q3 		$12.7M Sell
596,442
-187,404
-24% -$4.43M 0.01% 1169
2025
Q2 		$16.9M Buy
783,846
+134,636
+21% +$2.5M 0.02% 972
2025
Q1 		$10.8M Buy
649,210
+17,788
+3% +$323K 0.01% 1083
2024
Q4 		$11.6M Buy
631,422
+212,019
+51% +$3.42M 0.02% 1012
2024
Q3 		$6.45M Sell
419,403
-685,703
-62% -$11.4M 0.01% 1267
2024
Q2 		$18M Buy
1,105,106
+461,036
+72% +$7.44M 0.03% 644
2024
Q1 		$11.9M Buy
644,070
+363,811
+130% +$9.01M 0.02% 773
2023
Q4 		$8.77M Buy
280,259
+67,340
+32% +$1.61M 0.02% 784
2023
Q3 		$4.44M Buy
212,919
+188,080
+757% +$5.11M 0.01% 989
2023
Q2 		$595K Buy
+24,839
New +$552K ﹤0.01% 1474
2023
Q1 		– Sell
-30,721
Closed -$489K – 2484
2022
Q4 		$489K Buy
+30,721
New +$480K ﹤0.01% 1481
2022
Q2 		– Sell
-12,825
Closed -$311K – 2432
2022
Q1 		$311K Buy
+12,825
New +$310K ﹤0.01% 1770
2021
Q1 		– Sell
-48,226
Closed -$2.58M – 1863
2020
Q4 		$2.58M Buy
+48,226
New +$2.39M 0.04% 521
2020
Q3 		– Sell
-161,431
Closed -$7.83M – 1614
2020
Q2 		$7.83M Buy
+161,431
New +$7.75M 0.11% 219
2020
Q1 		– Sell
-5,940
Closed -$254K – 1073
2019
Q4 		$254K Buy
+5,940
New +$258K 0.01% 1299

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ACAD Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Acadia Pharmaceuticals (ACAD) stake by 21% in Q1 2026, selling an estimated $6.03M and leaving 950,299 shares worth $21.2M. The position accounts for 0.02% of the portfolio, ranked #855.

Qube Research & Technologies (QRT) first reported a position in ACAD in Q4 2019 and has held it in 17 quarters since. The position peaked at $32.1M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Qube Research & Technologies (QRT) held 950,299 shares of Acadia Pharmaceuticals worth $21.2M as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 252,302 Acadia Pharmaceuticals shares in Q1 2026, an estimated $6.03M.
  • Acadia Pharmaceuticals made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #855 holding.
  • Qube Research & Technologies (QRT) first reported a position in Acadia Pharmaceuticals in Q4 2019 and has held it in 17 quarters since.
  • Qube Research & Technologies (QRT)'s Acadia Pharmaceuticals position peaked at $32.1M in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.